Management of metastatic renal cell carcinoma patients with poor-risk features: Current status and future perspectives

Expert Review of Anticancer Therapy

Volumn 13, Issue 6, 2013, Pages 697-709

  Santoni, Matteo ^a   De Tursi, Michele ^b   Felici, Alessandra ^c   Lo Re, Giovanni ^d   Ricotta, Riccardo ^e   Ruggeri, Enzo Maria ^f   Sabbatini, Roberto ^g   Santini, Daniele ^h   Vaccaro, Vanja ^c   Milella, Michele ^c  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d Santa Maria Degli Angeli   (Italy)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f BELCOLLE HOSPITAL   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

mRCC; poor risk; risk stratification; tailored therapy; targeted therapies

Indexed keywords

BEVACIZUMAB; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; DRUG APPROVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LIVER DISEASE; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT; PATIENT CARE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POOR RISK PATIENT; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK ASSESSMENT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PALLIATIVE CARE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIROLIMUS; SULFONAMIDES; TOR SERINE-THREONINE KINASES;

EID: 84879358846     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.13.52     Document Type: Review

References (89)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012).
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 353(23), 2477-2490 (2005). (Pubitemid 41770167)
3. Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25(4), 793-812 (2011).
4. Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest. 28(3), 312-322 (2010).
5. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34(3), 193-205 (2008).
6. Milella M, Felici A. Biology of metastatic renal cell carcinoma. J. Cancer 2, 369-373 (2011).
7. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin. Oncol. 24(3), 284-290 (2012).
8. Posadas EM, Figlin RA. Systemic therapy in renal cell carcinoma: advancing paradigms. Oncology (Williston Park, NY) 26(3), 290-301 (2012).
9. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol. Oncol. Clin. North Am. 25(4), 835-852 (2011).
10. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 71(9), 1179-1191 (2011).
11. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist 16(Suppl. 2), 45-50 (2011).
12. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 16(Suppl. 2), 14-22 (2011).
13. Heng DY, Xie W, Regan MM et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14(2), 141-148 (2013).
14. Harshman LC, Xie W, Bjarnason GA et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a populationbased study. Lancet Oncol. 13(9), 927-935 (2012).
15. Manola J, Royston P, Elson P et al.; International Kidney Cancer Working Group. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin. Cancer Res. 17(16), 5443-5450 (2011).
16. Powles T, Hutson TE. Difficulty in predicting survival in metastatic renal cancer. Lancet Oncol. 13(9), 859-860 (2012).
17. Felici A, Bria E, Tortora G, Cognetti F, Milella M. Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. Expert Rev. Anticancer Ther. 12(12), 1545-1557 (2012).
18. Escudier B, Chevreau C, Lasset C et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J. Clin. Oncol. 17(7), 2039-2043 (1999). (Pubitemid 29318832)
19. McDermott DF, Ghebremichael MS, Signoretti S et al. The high-dose aldesleukin (HD IL-2) 'SELECT' trial in patients with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol. 28(Suppl. 15), Abstract 4514 (2010).
20. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20(9), 2376-2381 (2002). (Pubitemid 34441667)
21. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999). (Pubitemid 29368255)
22. Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J. Natl Compr. Cancer Netw. 7(6), 659-665 (2009).
23. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-? as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002). (Pubitemid 34032623)
24. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23(4), 832-841 (2005). (Pubitemid 46224183)
25. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110(3), 543-550 (2007). (Pubitemid 47106142)
26. Patil S, Figlin RA, Hutson TE et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 22(2), 295-300 (2011).
27. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27(34), 5794-5799 (2009).
28. Bukowski RM, Negrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin. Cancer Res. 10(18 Pt 2), 6310S-6314S (2004). (Pubitemid 39287484)
29. Escudier B, Bellmunt J, Négrier S et al. Phase III trial of bevacizumab plus interferon ?-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010).
30. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib compared with interferon ? in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(22), 3584-3590 (2009).
31. Hudes G, Carducci M, Tomczak P et al.; Global ARCC Trial. Temsirolimus, interferon ?, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007). (Pubitemid 46849157)
32. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon-? versus interferon-? monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
33. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
34. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 91(8), 1420-1424 (2004). (Pubitemid 39486341)
35. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 66(11), 5549-5554 (2006). (Pubitemid 43927103)
36. Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22(5), 909-918 (2004). (Pubitemid 41103603)
37. Zbrozek AS, Hudes G, Levy D et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics 28(7), 577-584 (2010).
38. Basso M, Cassano A, Schinzari G, Barone C. Temsirolimus: is improved survival the correct expression of drug activity? Oncologist 15(7), 790-791; author reply 792 (2010).
39. Ljungberg B, Cowan NC, Hanbury DC et al.; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur. Urol. 58(3), 398-406 (2010).
40. Bellmunt J, Guix M. The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations. BJU Int. 103(5), 572-577 (2009).
41. Escudier B, Pluzanska A, Koralewski P et al.; AVOREN Trial investigators. Bevacizumab plus interferon ?-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007). (Pubitemid 350296300)
42. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon ? compared with interferon ? monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol. 26(33), 5422-5428 (2008).
43. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon ? in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007). (Pubitemid 46089672)
44. Gore ME, Szczylik C, Porta C et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10(8), 757-763 (2009).
45. Heng DY, Elson P, Golshayan AR, Warren MA et al. A retrospective multicenter study of MSKCC poor-prognosis patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J. Clin. Oncol. 26(Suppl.), Abstract 16057 (2008).
46. Lee JL, Park I, Park K et al. Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features. J. Cancer Res. Clin. Oncol. 138(4), 687-693 (2012).
47. Karam JA, Wood CG. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy. Hematol. Oncol. Clin. North Am. 25(4), 753-764 (2011).
48. Kenney PA, Wood CG. Integration of surgery and systemic therapy for renal cell carcinoma. Urol. Clin. North Am. 39(2), 211-231 (2012).
49. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon ?-2b compared with interferon ?-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001). (Pubitemid 33126820)
50. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171(3), 1071-1076 (2004). (Pubitemid 38327529)
51. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-?-based immunotherapy compared with interferon-? alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358(9286), 966-970 (2001). (Pubitemid 32913522)
52. Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat. Rev. Urol. 6(7), 375-383 (2009).
53. Bex A, Powles T. Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when. Expert Rev. Anticancer Ther. 12(6), 787-797 (2012).
54. Margulis V, Matin SF, Wood CG. Resection of retroperitoneal nodal disease in patients with metastatic conventional renal cell carcinoma may improve survival. Curr. Opin. Urol. 18, 474-480 (2008).
55. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J. Clin. Oncol. 22(3), 454-463 (2004). (Pubitemid 41079774)
56. Fallick ML, McDermott DF, LaRock D, Long JP, Atkins MB. Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J. Urol. 158(5), 1691-1695 (1997). (Pubitemid 27433133)
57. Halbert RJ, Figlin RA, Atkins MB et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer 107(10), 2375-2383 (2006). (Pubitemid 44748520)
58. Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J. Urol. 185(1), 60-66 (2011).
59. Logan T, McDermott DF, Dutcher JP et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. J. Clin. Oncol. 2008 ASCO Annual Meeting Proceedings 26, 15S (2008) (May 20 Supplement).
60. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother. Oncol. 92(3), 329-333 (2009).
61. Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol. 21(7), 1232-1237 (2003). (Pubitemid 46606398)
62. Agarwala SS, Keilholz U, Gilles E et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur. J. Cancer 45(10), 1807-1814 (2009).
63. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J. Clin. Oncol. 30(27), 3402-3407 (2012).
64. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66(18), 8927-8930 (2006). (Pubitemid 44521105)
65. Sun M, Shariat SF, Cheng C et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur. Urol. 60(4), 644-661 (2011).
66. Zha X, Wang F, Wang Y et al. Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res. 71(1), 13-18 (2011).
67. Sun Q, Chen X, Ma J et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl Acad. Sci. USA 108(10), 4129-4134 (2011).
68. Linehan WM, Bratslavsky G, Pinto PA et al. Molecular diagnosis and therapy of kidney cancer. Annu. Rev. Med. 61, 329-343 (2010).
69. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366(10), 883-892 (2012).
70. Xu X, Hou Y, Yin X et al. Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell 148(5), 886-895 (2012).
71. Henske EP. The genetic basis of kidney cancer: why is tuberous sclerosis complex often overlooked? Curr. Mol. Med. 4(8), 825-831 (2004). (Pubitemid 39585727)
72. Maher ER. Von Hippel-Lindau disease. Curr. Mol. Med. 4(8), 833-842 (2004). (Pubitemid 39585728)
73. Linehan WM, Pinto PA, Bratslavsky G et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 115(10 Suppl.), 2252-2261 (2009).
74. Patard JJ, Leray E, Rioux-Leclercq N et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J. Clin. Oncol. 23(12), 2763-2771 (2005). (Pubitemid 46179466)
75. Capitanio U, Cloutier V, Zini L et al. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. BJU Int. 103(11), 1496-1500 (2009).
76. Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J. Clin. Oncol. 26(1), 127-131 (2008).
77. Stadler WM, Figlin RA, McDermott DF et al.; ARCCS Study Investigators. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5), 1272-1280 (2010).
78. Riechelmann RP, Chin S, Wang L et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am. J. Clin. Oncol. 31(2), 182-187 (2008). (Pubitemid 351519171)
79. Dutcher JP, de Souza P, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med. Oncol. 26(2), 202-209 (2009).
80. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit. Rev. Oncol. Hematol. 82(3), 323-337 (2012).
81. Escudier B, Osanto S, Ljungberg B et al. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat. Rev. 38(2), 127-132 (2012).
82. Porta C, Procopio G, Cartenì G et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 108(8 Pt 2), E250-E257 (2011).
83. Calvo E, Ravaud A, Bellmunt J. What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat. Rev. 39(4), 366-374 (2013).
84. González Larriba JL, Espinosa E, García Carbonero I et al. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a secondor subsequent-line therapy with a different mechanism of action. Cancer Metastasis Rev. 31(Suppl. 1), S11-S17 (2012).
85. Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev. Anticancer Ther. 11(4), 639-649 (2011).
86. Park K, Lee JL, Park I et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med. Oncol. 29(5), 3291-3297 (2012).
87. Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549-1555 (2012).
88. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011).
89. Santini D, Procopio G, Porta C et al. Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastases survey. J. Clin. Oncol. 30(Suppl.), Abstract 4627 (2012).